Less Ads, More Data, More Tools Register for FREE

Pin to quick picksYGEN.L Regulatory News (YGEN)

  • There is currently no data for YGEN

Projects Update

29 Sep 2008 07:00

RNS Number : 5036E
ViaLogy PLC
29 September 2008
 



ViaLogy Plc ("ViaLogy" or "the Company")

Projects Update

Pasadena, California - 29 September, 2008Vialogy PLC (AIM: VIY), the AiM-listed technology company, is pleased to announce significant developments in three of its major projects. 

Software installation in military base

The Company has been awarded a sub-contract from a major US defense system integrator for the insertion of ViaLogy's sensor interoperability platform software into an operating military base security system. ViaLogy will integrate the multiple perimeter surveillance systems on the base, simplifying operations and eliminating system failure in security deployment. 

More detailed information on the project and the names of the systems integrator firm and the specific military base cannot be disclosed for national security reasons.

In addition, SPM® was recently deployed by Los Angeles County first responders at a major sports event attended by over 90,000 fans to demonstrate and assess effectiveness in providing advance warning and crisis management in the event of a chemical or biological terrorist event. Following this success, LA County also deployed SPM to co-ordinate security and surveillance at the 60th Emmy Awards ceremony in Los Angeles. 

"The diversity of these SPM applications helps to position the product as the certified CBRNE (Chemical, Biological, Radiological, Nuclear and Explosive detection) and physical security sensor integration engine for purchases of enterprise-grade systems. We anticipate future customers will include state, local and federal procurement agencies, including the Department of Homeland Security, and system integrator firms", said Terry Bond, ViaLogy's Chairman.

New dates set for Oil & Gas validation

Hurricane Ike has caused a brief postponement of the ViaLogy-Atascosa Engineering partnership plans to drill its first well and thereby prove the value of ViaLogy's Quantum Resonance Interferometry (QRI™) technology which is being used to determine the oil reservoir's location, capacity and porosity, as well as the exact drill site. This adaptation of QRI is branded QuantumRD.

"Ike's unpredictable progress through Texas meant we had to delay preparations for erecting the drilling equipment", said Mr. Bond. "At one point it appeared that the site, near San Antonio, would be in the eye of the storm. Fortunately it transpired the area was on the perimeter and we sustained minimal damage."

While the project is a pilot, this is a fully operational extraction site and a strike should substantiate the effectiveness of the technology in the oil discovery process. Drilling is now scheduled for mid-October and results will be available towards the end of that month.

Aerial pipeline surveys in October

The second imminent application for QRI, called QSUB™, will be used to determine exact geolocation and condition of underground oil and gas pipelines. Proof-of-concept flights by Sky Research Inc of Ashland, Oregon, www.skyresearch.com, organised by ViaLogy and its partner firm ASTFS, are scheduled for this October. The aim is for QSUB technology to analyse data from airborne synthetic aperture radar (SAR) and light detection and ranging (LIDAR) sensors. ViaLogy has received strong indications of interest from leading pipeline firms in the success of the proof-of-concept work and in purchase of the operational service when available.

"There are almost 3 million kilometres of buried pipeline in the US alone", said Mr. Bond. "A cost-effective means of providing exact pipeline location and status is in high demand by both pipeline firms and regulatory agencies. We believe that the latest radar equipment, combined with QSUB data analysis will enable this to be done by aerial surveys."

Ends

Further information from:

ViaLogy

Robert W Dean, President & CEO - US +1 626-296-6337 (mobile: +1 703-589-3807)

Terry Bond, Chairman - UK & Europe +44 (0) 1235-834734 

Nominated Advisor (Seymour Pierce)

Mark Percy +44 (0) 20-7107-8000

Stockbroker - St. Helen's Capital PLC +44 (0) 20-7628 5582 

PR Consultants - Redleaf Communications 

Emma Kane / Samantha Robbins +44 (0) 20-7822-0200 

About ViaLogy: 

ViaLogy is a leading innovator of network-centric, real-time signal processing platforms for sensor applications. ViaLogy is currently deploying and designing computational systems, powered by its patented technologies, for applications in life sciences, public safety and security, surveillance, defense and geoseismology. Vialogy focuses on market driven problems where automation, timeliness, quality and reliability of information processing are essential. ViaLogy's core competency incorporates rapidly and accurately detecting weak signals buried in high noise background and clutter. This technology can be employed to solve problems involving sensor integration and information overload challenges involving video, telephony and control sensors, as well as for enhancement of numerous signal processing applications. For more information, visit our website at www.vialogy.com

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
RESBRGDCLDDGGII
Date   Source Headline
30th Nov 201511:20 amRNSNotice of Results
12th Nov 20157:00 amRNSPositive independent study results for IONA test
28th Oct 20157:00 amRNSAppointment to the Board
15th Oct 20153:56 pmRNSWorld first: in-house antenatal reflex screening
14th Oct 20157:00 amRNSClinical laboratory with expanded capacity opened
14th Oct 20157:00 amRNSHolding(s) in Company
13th Oct 20154:08 pmRNSResult of AGM
13th Oct 20152:20 pmRNSHolding(s) in Company
13th Oct 20157:01 amRNSAGM Statement
13th Oct 20157:00 amRNSPremaitha collaborates with Wolfson screening lab
12th Oct 20157:00 amRNSIndependent study of the IONA® test published
2nd Oct 20157:00 amRNSPremaitha appoints Greek distributor
1st Oct 20154:14 pmRNSPatent Infringement Proceedings Update
22nd Sep 20157:00 amRNSFinal Results
22nd Sep 20157:00 amRNSPremaitha signs contract for IONA test in Chile
15th Jul 20157:00 amRNSGrant of Options
13th Jul 20152:04 pmRNSHolding(s) in Company
6th Jul 20157:00 amRNSCQC accreditation for new NIPT lab
2nd Jul 20152:59 pmRNSCompletion of placing to raise £8 million
2nd Jul 20157:00 amRNSProposed placing to raise approximately £8 million
24th Jun 20157:00 amRNSNew IONA test clinical data showcased
22nd Jun 20157:00 amRNSNew contract for IONA® test
19th Jun 20157:00 amRNSTrading Update
4th Jun 20157:00 amRNSAppointment of Chief Financial Officer
5th May 20157:01 amRNSPremaitha Files Robust Defence with UK High Court
29th Apr 20151:53 pmRNSReissue of Options
31st Mar 20157:00 amRNSNew Contract for IONA test in Poland
23rd Mar 20159:53 amRNSLondon NHS trust teams up with Premaitha Health
16th Mar 20159:40 amRNSNotice of Patent Infringement Proceedings
16th Mar 20157:00 amRNSPremaitha Health signs first NIPT agreement
5th Feb 20157:00 amRNSCE Mark and Launch of the IONA test
30th Jan 20157:00 amRNSCommercial Launch Preparation Update
10th Dec 20147:00 amRNSResults for 7 months to 30 September 2014
25th Nov 20147:00 amRNSNotice of Half Year Results and IONA Test Showcase
4th Nov 201412:07 pmRNSResult of AGM
4th Nov 20147:00 amRNSAGM Statement
2nd Oct 20147:00 amRNSGrant of Options
30th Sep 20147:00 amRNSPublication of Annual Report and Notice of AGM
7th Jul 20144:47 pmRNSHolding(s) in Company
4th Jul 20144:28 pmRNSHolding(s) in Company
4th Jul 20147:00 amRNSFirst Day of Dealings on AIM
3rd Jul 20143:42 pmRNSChange of Name
3rd Jul 201411:36 amRNSResult of EGM
1st Jul 201410:47 amRNSOpen Offer Oversubcribed
13th Jun 20147:30 amRNSRestoration - ViaLogy Plc
13th Jun 20147:30 amRNSSchedule 1 - ViaLogy Plc
13th Jun 20147:00 amRNSPublication of Admission Document & Lifting of...
13th Jun 20147:00 amRNSDirectorate Change
13th Jun 20147:00 amRNSFinal Results
15th Apr 201412:30 pmRNSSuspension - Vialogy plc

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.